Home Newsfeeds Morgan Stanley Maintains Equal-Weight on Jackson Finl, Lowers Price Target to $33

Morgan Stanley Maintains Equal-Weight on Jackson Finl, Lowers Price Target to $33

Morgan Stanley analyst Nigel Dally maintains Jackson Finl (NYSE:JXN) with a Equal-Weight and lowers the price target from $40 to $33.

byBenzinga Newsdesk

July 6, 2022

1 minute read

Morgan Stanley analyst Nigel Dally maintains Jackson Finl (NYSE:JXN) with a Equal-Weight and lowers the price target from $40 to $33.

Analyst Ratings

Expert Ratings for Hubbell

By Benzinga Insights

July 10, 4:00 PM

Hubbell (NYSE:HUBB) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

HUBB

Confounding Trade? Cathie Wood Dumps $50M In Nvidia Shares Just 2 Weeks After Major Buy And A Day Ahead Of Earnings

By Bhavik Nair

August 24, 3:14 AM

Cathie Wood-led Ark Investment Management dumped over 293,000 shares of NVIDIA Corporation (NASDAQ: NVDA) on Tuesday via two of the firm’s exchange-traded funds.

ARKK

Tiffany Is Turning CryptoPunk NFTs Into Diamond Chains: Here’s How Much ETH You’ll Have To Shell Out

By Samyuktha Sriram

July 31, 10:29 PM

Luxury jewelry brand Tiffany & Co. is selling 250 exclusive diamond pendants to CryptoPunk NFT holders.

ETH

FDA Asks For Additional Successful Trial To Approve Soligenix’s Rare Cancer Candidate

By Vandana Singh

April 14, 11:39 AM

Soligenix Inc (NASDAQ:SNGX) convened a Type A Meeting with the FDA, discussing the contents of a refusal to file (RTF)…

SNGX

Morgan Stanley Maintains Equal-Weight on Jackson Finl, Lowers Price Target to $33

Related Posts

Expert Ratings for Hubbell

Confounding Trade? Cathie Wood Dumps $50M In Nvidia Shares Just 2 Weeks After Major Buy And A Day Ahead Of Earnings

Tiffany Is Turning CryptoPunk NFTs Into Diamond Chains: Here’s How Much ETH You’ll Have To Shell Out

FDA Asks For Additional Successful Trial To Approve Soligenix’s Rare Cancer Candidate